![](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3631fc46820d52d77365e197cf6a48643c9edc74-1200x686.jpg?fit=crop&auto=format)
Mitigating ILD Following T-DXd in HR+, HER2-Low Metastatic Breast Cancer
In a conversation with CancerNetwork®, Paolo Tarantino, MD, discussed strategies for mitigating interstitial lung disease (ILD) in patients with hormone receptor–positive, HER2-low or HER2-ultralow metastatic breast cancer who receive fam-trastuzumab …